Cargando…

Perspective of Use of Antiviral Peptides against Influenza Virus

The threat of a worldwide influenza pandemic has greatly increased over the past decade with the emergence of highly virulent avian influenza strains. The increased frequency of drug-resistant influenza strains against currently available antiviral drugs requires urgent development of new strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Skalickova, Sylvie, Heger, Zbynek, Krejcova, Ludmila, Pekarik, Vladimir, Bastl, Karel, Janda, Jozef, Kostolansky, Frantisek, Vareckova, Eva, Zitka, Ondrej, Adam, Vojtech, Kizek, Rene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632391/
https://www.ncbi.nlm.nih.gov/pubmed/26492266
http://dx.doi.org/10.3390/v7102883
_version_ 1782399019681579008
author Skalickova, Sylvie
Heger, Zbynek
Krejcova, Ludmila
Pekarik, Vladimir
Bastl, Karel
Janda, Jozef
Kostolansky, Frantisek
Vareckova, Eva
Zitka, Ondrej
Adam, Vojtech
Kizek, Rene
author_facet Skalickova, Sylvie
Heger, Zbynek
Krejcova, Ludmila
Pekarik, Vladimir
Bastl, Karel
Janda, Jozef
Kostolansky, Frantisek
Vareckova, Eva
Zitka, Ondrej
Adam, Vojtech
Kizek, Rene
author_sort Skalickova, Sylvie
collection PubMed
description The threat of a worldwide influenza pandemic has greatly increased over the past decade with the emergence of highly virulent avian influenza strains. The increased frequency of drug-resistant influenza strains against currently available antiviral drugs requires urgent development of new strategies for antiviral therapy, too. The research in the field of therapeutic peptides began to develop extensively in the second half of the 20(th) century. Since then, the mechanisms of action for several peptides and their antiviral prospect received large attention due to the global threat posed by viruses. Here, we discussed the therapeutic properties of peptides used in influenza treatment. Peptides with antiviral activity against influenza can be divided into three main groups. First, entry blocker peptides such as a Flupep that interact with influenza hemagglutinin, block its binding to host cells and prevent viral fusion. Second, several peptides display virucidal activity, disrupting viral envelopes, e.g., Melittin. Finally, a third set of peptides interacts with the viral polymerase complex and act as viral replication inhibitors such as PB1 derived peptides. Here, we present a review of the current literature describing the antiviral activity, mechanism and future therapeutic potential of these influenza antiviral peptides.
format Online
Article
Text
id pubmed-4632391
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-46323912015-11-23 Perspective of Use of Antiviral Peptides against Influenza Virus Skalickova, Sylvie Heger, Zbynek Krejcova, Ludmila Pekarik, Vladimir Bastl, Karel Janda, Jozef Kostolansky, Frantisek Vareckova, Eva Zitka, Ondrej Adam, Vojtech Kizek, Rene Viruses Review The threat of a worldwide influenza pandemic has greatly increased over the past decade with the emergence of highly virulent avian influenza strains. The increased frequency of drug-resistant influenza strains against currently available antiviral drugs requires urgent development of new strategies for antiviral therapy, too. The research in the field of therapeutic peptides began to develop extensively in the second half of the 20(th) century. Since then, the mechanisms of action for several peptides and their antiviral prospect received large attention due to the global threat posed by viruses. Here, we discussed the therapeutic properties of peptides used in influenza treatment. Peptides with antiviral activity against influenza can be divided into three main groups. First, entry blocker peptides such as a Flupep that interact with influenza hemagglutinin, block its binding to host cells and prevent viral fusion. Second, several peptides display virucidal activity, disrupting viral envelopes, e.g., Melittin. Finally, a third set of peptides interacts with the viral polymerase complex and act as viral replication inhibitors such as PB1 derived peptides. Here, we present a review of the current literature describing the antiviral activity, mechanism and future therapeutic potential of these influenza antiviral peptides. MDPI 2015-10-20 /pmc/articles/PMC4632391/ /pubmed/26492266 http://dx.doi.org/10.3390/v7102883 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Skalickova, Sylvie
Heger, Zbynek
Krejcova, Ludmila
Pekarik, Vladimir
Bastl, Karel
Janda, Jozef
Kostolansky, Frantisek
Vareckova, Eva
Zitka, Ondrej
Adam, Vojtech
Kizek, Rene
Perspective of Use of Antiviral Peptides against Influenza Virus
title Perspective of Use of Antiviral Peptides against Influenza Virus
title_full Perspective of Use of Antiviral Peptides against Influenza Virus
title_fullStr Perspective of Use of Antiviral Peptides against Influenza Virus
title_full_unstemmed Perspective of Use of Antiviral Peptides against Influenza Virus
title_short Perspective of Use of Antiviral Peptides against Influenza Virus
title_sort perspective of use of antiviral peptides against influenza virus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632391/
https://www.ncbi.nlm.nih.gov/pubmed/26492266
http://dx.doi.org/10.3390/v7102883
work_keys_str_mv AT skalickovasylvie perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT hegerzbynek perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT krejcovaludmila perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT pekarikvladimir perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT bastlkarel perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT jandajozef perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT kostolanskyfrantisek perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT vareckovaeva perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT zitkaondrej perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT adamvojtech perspectiveofuseofantiviralpeptidesagainstinfluenzavirus
AT kizekrene perspectiveofuseofantiviralpeptidesagainstinfluenzavirus